|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation显示文摘The intimate connection and the strict mutual cooperation between the gut and the liver realizes a functional entity called gut-liver axis.The integrity of intestinal barrier is crucial for the maintenance of liver homeostasis.In this mutual relationship,the liver acts as a second firewall towards potentially harmful substances translocated from the gut,and is,in turn,is implicated in the regulation of the barrier.Increasing evidence has highlighted the relevance of increased intestinal permeability and consequent bacterial translocation in the development of liver damage.In particular,in patients with non-alcoholic fatty liver disease recent hypotheses are considering intestinal permeability impairment,diet and gut dysbiosis as the primary pathogenic trigger.In advanced liver disease,intestinal permeability is enhanced by portal hypertension.The clinical consequence is an increased bacterial translocation that further worsens liver damage.Furthermore,this pathogenic mechanism is implicated in most of liver cirrhosis complications,such as spontaneous bacterial peritonitis,hepatorenal syndrome,portal vein thrombosis,hepatic encephalopathy,and hepatocellular carcinoma.After liver transplantation,the decrease in portal pressure should determine beneficial effects on the gut-liver axis,although are incompletely understood data on the modifications of the intestinal permeability and gut microbiota composition are still lacking.How the modulation of the intestinal permeability could prevent the initiation and progression of liver disease is still an uncovered area,which deserves further attention. | Alberto Nicoletti Francesca Romana Ponziani Marco Biolato Venanzio Valenza Giuseppe Marrone Gabriele Sganga Antonio Gasbarrini Luca Miele Antonio Grieco | 2019 | World Journal of Gastroenterology2019，25，33： | 19 |
| 2 | Liver toxicity of rosuvastatin therapy显示文摘We report here a case of clinically significant liver toxicity after a brief course of rosuvastatin, which is the first statin approved by the regulatory authorities since the withdrawal of cerivastatin. Whether rosuvastatin has a greater potential compared with other statins to damage the liver is unclear and the involved mechanisms are also unknown. However, rosuvastatin is taken up by hepatocytes more selectively and more efficiently than other statins, and this may reasonably represent an important variable to explain the hepatotoxic potential of rosuvastatin. Our report supports the view that a clinically significant risk of liver toxicity should be considered even when rosuvastatin is given at the range of doses used in common clinical practice. | Giuseppe Famularo Luca Miele Giovanni Minisola Antonio Grieco | 2007 | World Journal of Gastroenterology2007，13，8： | 8 |
| 3 | A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome显示文摘AIM:To test the efficacy of a proprietary nutraceutical combination in reducing insulin resistance associated with the metabolic syndrome(MetS).METHODS:Sixty-four patients with MetS followed at a tertiary outpatient clinic were randomly assigned to receive either placebo or a proprietary nutraceutical combination(AP)consisting of berberine,policosanol and red yeast rice,in a prospective,double-blind,placebo-controlled study.Evaluations were performed at baseline and after 18 wk of treatment.The homeostasis model assessment of insulin resistance(HOMAIR)index was the primary outcome measure.Secondary endpoints included lipid panel,blood glucose and insulin fasting,after a standard mixed meal and after an oral glucose tolerance test(OGTT),ow-mediated dilation(FMD),and waist circumference.RESULTS:Fifty nine patients completed the study,2 withdrew because of adverse effects.After 18 wk there was a signif icant reduction in the HOMA-IR index in the AP group compared with placebo(ΔHOMA respectively-0.6 ± 1.2 vs 0.4 ± 1.9;P < 0.05).Total and low density lipoprotein cholesterol also significantly decreased in the treatment arm compared with placebo(Δlow density lipoprotein cholesterol-0.82 ± 0.68 vs-0.13 ± 0.55 mmol/L;P < 0.001),while triglycerides,high density lipoprotein cholesterol,and the OGTT were not affected.In addition,there were significant reductions in blood glucose and insulin after the standard mixed meal,as well as an increase in FMD(ΔFMD 1.9 ± 4.2 vs 0 ± 1.9 %;P < 0.05)and a significant reduction in arterial systolic blood pressure in the AP arm.CONCLUSION:This short-term study shows that AP has relevant beneficial effects on insulin resistance and many other components of MetS. | Flora Affuso Valentina Mercurio Antonio Ruvolo Concetta Pirozzi Filomena Micillo Guido Carlomagno Fabrizia Grieco Serafino Fazio | 2012 | World Journal of Cardiology2012，4，3： | 7 |
| 4 | Ethanol injection is highly effective for hepatocellular carcinoma smaller than 2cm显示文摘AIM:To analyze the long-term prognosis in a cohort of western cirrhotic patients with single hepatocellular carcinoma treated with ethanol injection.METHODS:One-hundred forty-eight patients with solitary hepatocellular carcinoma were enrolled.The tumor diameter was lower than 2 cm in 47 patients but larger in the remaining 101 patients.The impact of some pretreatment clinical and laboratory parameters and of tumor recurrence on patients' survival was assessed.RESULTS:Among the pre-treatment parameters,only a tumor diameter of less than 2 cm was an independent prognostic factor of survival.The occurrence of new nodules in other liver segments and the neoplastic portal invasion were linked to a poorer prognosis at univariate analysis.Patients with a single hepatocellular carcinoma smaller than 2 cm showed a better 5-year cumulativesurvival(73.0% vs 47.9%)(P = 0.009),3-year local recurrence rate(29.1% vs 51.5%)(P = 0.011),and 5-year distant intrahepatic recurrence rate(52.9% vs 62.8%)(P = 0.054) compared to patients with a larger tumor.CONCLUSION:The 5-year survival rate of patients with single hepatocellular carcinoma < 2 cm undergoing ethanol injection is excellent and comparable to that achieved using radiofrequency ablation. | Maurizio Pompili Erica Nicolardi Valeria Abbate Luca Miele Laura Riccardi Marcello Covino Nicoletta De Matthaeis Antonio Grieco Raffaele Landolfi Gian Ludovico Rapaccini | 2011 | World Journal of Gastroenterology2011，17，26： | 6 |
| 5 | Intestinal permeability after Mediterranean diet and low-fat diet in non-alcoholic fatty liver disease显示文摘BACKGROUND In non-alcoholic fatty liver disease(NAFLD), a high-fat or high-fructose diet increases intestinal permeability and promotes derangement of the gut-liver axis.We hypothesize that, diet could be able to modulate intestinal permeability in patients with NAFLD.AIM To detect diet-induced modification of intestinal permeability in patients with NAFLD undergoing a Mediterranean diet or a low-fat diet.METHODS The current study was a dietary intervention for non-diabetic, patients with biopsy-verified NAFLD and increased transaminases. A crossover design was employed: participants underwent 16 weeks of Mediterranean diet, 16 wk of free wash-out, and 16 weeks of low-fat diet. Both diets were hypocaloric and no consumption of supplements was allowed. All patients were followed bimonthly by a dietitian. Evaluations of clinical and metabolic parameters were completed at baseline and at the end of each dietary period. Intestinal permeability was assessed by chromium-51 ethylene diamine tetraacetate excretion testing(51 CrEDTA).RESULTS Twenty Caucasian patients, 90% male, median age 43 years, body mass index(BMI) 30.9, with biopsy-verified NAFLD were enrolled. At the end of 16 weeks of a Mediterranean diet, a significant reduction in mean body weight(-5.3 ± 4.1 kg,P = 0.003), mean waist circumference(-7.9 ± 4.9 cm, P = 0.001), and mean transaminase levels [alanine aminotransferase(ALT)-28.3 ± 11.9 IU/L, P =0.0001; aspartate aminotransferase(AST)-6.4 ± 56.3 IU/L, P = 0.01] were observed. These benefits were maintained after 16 wk of wash-out and also after16 wk of low-fat diet, without further improvements. Fourteen of the 20 patients had intestinal permeability alteration at baseline(mean percentage retention of51 Cr-EDTA = 5.4%), but no significant changes in intestinal permeability were observed at the end of the 16 wk of the Mediterranean diet or 16 wk of the low-fat diet.CONCLUSION Mediterranean diet is an effective strategy for treating overweight, visceral obesity and serum transaminase in patients with NAFLD. If the Mediterranean diet can improve intestinal permeability in patients with NAFLD, it deserves further investigation. | Marco Biolato Fiorella Manca Giuseppe Marrone Consuelo Cefalo Simona Racco Giacinto A Miggiano Venanzio Valenza Antonio Gasbarrini Luca Miele Antonio Grieco | 2019 | World Journal of Gastroenterology2019，25，4： | 4 |
| 6 | Tumor necrosis factor-α inhibitors and chronic hepatitis C:A comprehensive literature review显示文摘Tumor necrosis factor-α(TNF-α)inhibitors are known to increase reactivation of concurrent chronic hepatitis B,but their impact on the hepatitis C virus(HCV)is controversial.Some conditions of immunosuppression,such as liver transplantation,typically cause an increase in the rate of HCV evolution.Inhibition of TNF-α,a cytokine involved in the apoptotic signaling pathway of hepatocytes infected by HCV,could potentially increase viral replication.Currently available clinical data appear to contradict this hypothesis.A review of medical literature revealed that a total of 216 patients with HCV were exposed to one or more treatments with TNF-αinhibitors,with a median observation time of 1.2 years and 260 cumulative patient-years of exposure.Only three cases of drug withdrawal due to suspected HCV liver disease recrudescence were reported.Treatment with TNF-αinhibitors in patients with HCV infection appears to be safe in the short term,but there are insufficient data to assess their long-term safety.Universal screening for HCV before beginning treatment with TNF-αinhibitors is currently controversial.The presence of HCV is not a contraindication to therapy with TNF-αinhibitors,with the exception of cirrhotic patients.In cases of cirrhosis,the benefit/risk ratio should be evaluated at the individual level.Prior to treatment with TNF-αinhibitors,patients with HCV should be referred to a hepatologist to determine the necessity of hepatic disease assessment,using liver biopsy or noninvasive methods,and the potential indication for antiviral therapy.In patients with HCV infection who are treated with TNF-αinhibitors,liver function monitoring every three months is advised. | Maurizio Pompili Marco Biolato Luca Miele Antonio Grieco | 2013 | World Journal of Gastroenterology2013，19，44： | 4 |
| 7 | Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C显示文摘Hepatitis C virus(HCV) infection has been a global health problem for decades, due to the high number of infected people and to the lack of effective and welltolerated therapies. In the last 3 years, the approval of new direct acting antivirals characterized by high rates of virological clearance and excellent tolerability has dramatically improved HCV infection curability, especially for patients with advanced liver disease and for liver transplant recipients. Long-term data about the impact of the new direct acting antivirals on liver fibrosis and liver disease-related outcomes are not yet available, due to their recent introduction. However, previously published data deriving from the use of pegylatedinterferon and ribavirin lead to hypothesizing that we are going to observe, in the future, a reduction in mortality and in the incidence of hepatocellular carcinoma, as well as a regression of fibrosis for people previously affected by hepatitis C. In the liver transplant setting, clinical improvement has already been described after treatment with the new direct acting antivirals, which has often led to patients delisting. In the future, this may hopefully reduce the gap between liver organ request and availability, probably expanding liver transplant indications to other clinical conditions. Therefore, these new drugs are going to change the natural history of HCV-related liver disease and the epidemiology of HCV infection worldwide. However, the global consequences will depend on treatment accessibility and on the number of countries that could afford the use of the new direct acting antivirals. | Francesca Romana Ponziani Francesca Mangiola Cecilia Binda Maria Assunta Zocco Massimo Siciliano Antonio Grieco Gian Lodovico Rapaccini Maurizio Pompili Antonio Gasbarrini | 2017 | World Journal of Hepatology2017，9，7： | 3 |
| 8 | A Controller-Based Architecture for Information Centric Network Construction and Topology management显示文摘Information-Centric Networking(ICN) has recently emerged as a result of the increased demand to access contents regardless of their location in the network services. This new approach facilitates content distribution as a service of the network with lower delay and higher security in comparison with the current IP network. Applying ICN in current IP infrastructure leads to major complexities. One approach to deploy ICN with less complexity is to integrate ICN with Software Defined Networking(SDN). The SDN controller manages the content distribution, caching, and routing based on the users' requests. In this paper, we extend these context by addressing the ICN topology management problem over the SDN network to achieve an improved user experience as well as network performance. In particular, a centralized controller is designed to construct and manage the ICN overlay. Experimental results indicate that this adopted topology management strategy achieves high performance, in terms of low failure in interest satisfaction and reduced download time compared to a plain ICN. | Zeinab Zali Massoud Reza Hashemi Ilaria Cianci Alfredo Grieco Gennaro Boggia | 2018 | China Communications2018，15，7： | 2 |
| 9 | Spread-spectrum signal acquisition: Method and technology显示文摘 | Rappaport S S Grieco D M | 1984 | IEEE Commun Mag1984，22，6： | 2 |
| 10 | Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients显示文摘 | Giuseppe Marazzi Luca Cacciotti Francesco Pelliccia Luigi Iaia Maurizio Volterrani Giuseppe Caminiti Barbara Sposato Rosalba Massaro Fabrizia Grieco Giuseppe Rosano | 2011 | Advances in Therapy2011，，12： | 2 |
| 11 | Minimum platelet count threshold before invasive procedures in cirrhosis:Evolution of the guidelines显示文摘Cirrhotic patients with severe thrombocytopenia are at increased risk of bleeding during invasive procedures.The need for preprocedural prophylaxis aimed at reducing the risk of bleeding in cirrhotic patients with thrombocytopenia who undergo scheduled procedures is assessed via the platelet count;however,establishing a minimum threshold considered safe is challenging.A platelet count≥50000/μL is a frequent target,but levels vary by provider,procedure,and specific patient.Over the years,this value has changed several times according to the different guidelines proposed in the literature.According to the latest guidelines,many procedures can be performed at any level of platelet count,which should not necessarily be checked before the procedure.In this review,we aim to investigate and describe how the guidelines have evolved in recent years in the evaluation of the minimum platelet count threshold required to perform different invasive procedures,according to their bleeding risk. | Marco Biolato Federica Vitale Tiziano Galasso Antonio Gasbarrini Antonio Grieco | 2023 | World Journal of Gastrointestinal Surgery2023，15，2： | 2 |
| 12 | Direct oral anticoagulant administration in cirrhotic patients with portal vein thrombosis:What is the evidence?显示文摘In recent years,the traditional concept that cirrhosis-related coagulopathy is an acquired bleeding disorder has evolved.Currently,it is known that in cirrhotic patients,the hemostatic system is rebalanced,which involves coagulation factors,fibrinolysis and platelets.These alterations disrupt homeostasis,skewing it toward a procoagulant state,which can lead to thromboembolic manifestations,especially when hemodynamic and endothelial factors co-occur,such as in the portal vein system in cirrhosis.Portal vein thrombosis is a common complication of advanced liver cirrhosis that negatively affects the course of liver disease,prognosis of cirrhotic patients and success of liver transplantation.It is still debated whether portal vein thrombosis is the cause or the consequence of worsening liver function.Anticoagulant therapy is the mainstay treatment for acute symptomatic portal vein thrombosis.In chronic portal vein thrombosis,the role of anticoagulant therapy is still unclear.Traditional anticoagulants,vitamin K antagonists and low-molecular-weight heparin are standard-of-care treatments for portal vein thrombosis.In the last ten years,direct oral anticoagulants have been approved for the prophylaxis and treatment of many thromboembolicrelated diseases,but evidence on their use in cirrhotic patients is very limited.The aim of this review was to summarize the evidence about the safety and effectiveness of direct oral anticoagulants for treating portal vein thrombosis in cirrhotic patients. | Marco Biolato Mattia Paratore Luca Di Gialleonardo Giuseppe Marrone Antonio Grieco | 2022 | World Journal of Hepatology2022，14，4： | 2 |
| 13 | Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease显示文摘 | P. Loria L.E. Adinolfi S. Bellentani E. Bugianesi A. Grieco S. Fargion A. Gasbarrini C. Loguercio A. Lonardo G. Marchesini F. Marra M. Persico D. Prati G. Svegliati- Baroni | 2010 | Digestive and Liver Disease2010，，4： | 2 |
| 14 | Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease显示文摘 | Luca Miele Venanzio Valenza Giuseppe La Torre Massimo Montalto Giovanni Cammarota Riccardo Ricci Roberta Mascianà Alessandra Forgione Maria L. Gabrieli Germano Perotti Fabio M. Vecchio Gianlodovico Rapaccini Giovanni Gasbarrini Chris P. Day Antonio Grieco | 2009 | Hepatology2009，，6： | 2 |
| 15 | Field‐practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy显示文摘 | Massimo Iavarone Giuseppe Cabibbo Fabio Piscaglia Claudio Zavaglia Antonio Grieco Erica Villa Calogero Cammà Massimo Colombo | 2011 | Hepatology2011，，6： | 2 |
| 16 | Complications of labor analgesia :epidural versus combined spinal epidural techniques显示文摘 | Norris MC Grieco WM Borkowski M | 1994 | Anesth Analg1994，79，3： | 1 |
| 17 | Degree of innovativeness and market structure: A model显示文摘 | Grieco D | 2007 | Iefai University Journal of Managerial Economics2007，14，2： | 1 |
| 18 | Performance evaluation and comparison of Westwood + , New Reno, and Vegas TCP congestion control 显示文摘 | Grieco L A Mascolo S | 2004 | ACM SIGCOMM Computer Commu- nication Review2004，34，2： | 1 |
| 19 | Complication of labor analgesia epidural versus combined spinal-epidural techniques 显示文摘 | Norris M C Grieco W M Borkowski M el al | 1995 | J Anesth Analg1995，79，： | 1 |
| 20 | Oncologic Colorectal Resection, Not Advanced Endoscopic Polypectomy, Is the Best Treatment for Large Dysplastic Adenomas显示文摘 | Joon Ho Jang Emre Balik Daniel Kirchoff Wouter Tromp Anjali Kumar Michael Grieco Daniel L. Feingold Vesna Cekic Linda Njoh Richard L. Whelan | 2012 | Journal of Gastrointestinal Surgery2012，，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员